Tongxinluo reduces brain edema and inhibits post-ischemic inflammation after middle cerebral artery occlusion in rats

详细信息    查看全文

• 作者：Min Cai^a ; ^{naphel1986@hotmail.com" class="auth_mail" title="E-mail the corresponding author} ; Zhonghai Yu^a ; ¹ ; ^{yuzhonghai0715@126.com" class="auth_mail" title="E-mail the corresponding author} ; Lili Wang^b ; ^{751501231@qq.com" class="auth_mail" title="E-mail the corresponding author} ; Xiaoling Song^a ; ^{songxl2016@163.com" class="auth_mail" title="E-mail the corresponding author} ; Jingsi Zhang^a ; ^{jingsiz@163.com" class="auth_mail" title="E-mail the corresponding author} ; Zhennian Zhang^a ; ^{zhennian2000@163.com" class="auth_mail" title="E-mail the corresponding author} ; Wen Zhang^a ; ^{zw8536899@163.com" class="auth_mail" title="E-mail the corresponding author} ; Wenwei Li^a ; ^{wenweili2000@aliyun.com" class="auth_mail" title="E-mail the corresponding author} ; Jun Xiang^a ; ^{chelsea_jx@hotmail.com" class="auth_mail" title="E-mail the corresponding author} ; Dingfang Cai^a ; ^{dingfangcai@163.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Ginsenoside Rg1 (PubChem CID ; 441923) ; Hirudin (PubChem CID ; 72941487) ; Buthotoxin (PubChem CID ; 20054854) ; Paeoniflorin (PubChem CID ; 442534) ; Chitin(PubChem CID ; 6857375) ; Santalol ; alpha- and beta- (PubChem CID ; 24832101) ; beta-Boswellic acid (PubChem CID ; 168928) ; Isoflavone (PubChem CID ; 72304) ; Jujuboside A (PubChem CID ; 171446)
• 刊名：Journal of Ethnopharmacology
• 出版年：2016
• 出版时间：2 April 2016
• 年：2016
• 卷：181
• 期：Complete
• 页码：136-145
• 全文大小：4879 K

文摘

Tongxinluo (TXL), a widely used traditional Chinese medicine, has been proved multiple therapeutic effects in cerebral ischemic infraction. The purpose of this study was to investigate the protective effects of TXL on the brain edema and post-ischemic inflammatory response.

Materials and Methods

Middle cerebral artery occlusion in the rat was used as the ischemia model. Rats were treated with TXL. In the first stage, the best dosage was chosen based on functional assessment and infarct size. In the second stage, rats were randomly divided into 5 groups: sham control (sham), ischemia and reperfusion (IR) 24 h, TXL24h, I/R72h, TXL72h. TXL(1.6 g/kg/day) administration was pre-performed for 3 days in TXL groups, and was post-performed for 24 h (TXL24h group) or 72 h (TXL72h group). Brain edema was measured by water content, MRI and AQP4 expression. Iba1, HMGB1, TLR4, NF-κB expression were examined by immunofluorescence staining or Western blot. TNF-α was determined by enzyme-linked immunosorbent assay.

Results

High dose (1.6 g/kg/day) of TXL remarkably reduced neurological deficit scores and cerebral infarct area. Compared with those results of I/R24h group, pre-post treatment with TXL for 3 days decreased brain water content, down-regulated AQP4 expression, lowered relative signal intensity of T2WI, reduced lesion volume ratio, and inhibited the activation of microglia, HMGB1, TLR4, NF-κB and TNF-α.

Conclusions

These results indicated that the TXL pre-post treatment for 3 days could be an effective therapy for brain ischemia by inhibiting the development of brain edema and post-ischemic inflammation.